Make more informed purchasing decisions with our new product availability and delivery estimate feature, now available on all product pages, in your cart, and during checkout.
Sign In
New to º£½ÇÆƽâ°æ?
Register for an account to quickly and easily purchase products online and for one-click access to all educational content.
Predictive methods are needed to increase the chance of success in your drug programs before clinical trials. Organoids are a beneficial tool in drug discovery and toxicity testing, aiding target discovery, validation, and pre-clinical testing. Organoid models provide a more physiologically relevant cellular composition and tissue structure than standard 2D models, with increased accuracy and higher throughput. Additionally, patient-derived organoids can be used to predict drug toxicity and efficacy, allowing you to make precise and confident decisions to advance your drug candidates.
Learn how organoids can help your drug-discovery workflow below.
Drs Bas Trietsch, Chief Technology Officer at MIMETAS, and Jenna Moccia, Director of Product Management at º£½ÇÆƽâ°æ Technologies, discuss the challenges that lead pharma companies to adopt advanced in vitro models, such as organoids and organ-on-a-chip, and the benefits they see after incorporating these systems in their research.
